Big drug makers keeping a close eye on Neurontin lawsuit

04/19/2004 | U.S. News & World Report

The legal battle over the marketing practices surrounding the epilepsy drug Neurontin and its off-label uses has major pharmaceutical companies waiting anxiously for a decision. The suit claims Parke-Davis, now part of Pfizer, engaged in illegal off-label promotion, and a victory for the plaintiff could lead to investigations of other drug companies' practices in the off-label area and force companies to look closely at their compliance and training practices. Some say the federal government is interested in a crackdown on off-label uses to cut its costs under the new Medicare prescription drug law.

View Full Article in:

U.S. News & World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD